Immedica Acquired by KKR and Impilo in Strategic Move
Deal News | Jan 24, 2025 | CVC Capital Partners
The article announces that CVC Credit, the credit management arm of CVC Capital Partners, has provided debt financing for the acquisition of Immedica Pharma by KKR and Impilo. Immedica, a Swedish pharmaceutical company, focuses on launching and commercializing drugs for rare and specialty diseases and operates in over 50 countries. The company's acquired capabilities span various pharmaceutical sectors, including marketing, sales, and pharmacovigilance. CVC Credit highlights Immedica’s profitable growth trajectory since its inception in 2018 and expresses eagerness to support its future expansion.
Sectors
- Pharmaceuticals
- Investment Management
Geography
- Sweden – Immedica Pharma is headquartered in Stockholm, Sweden.
- Global – Immedica operates a distribution network reaching over 50 countries worldwide.
Industry
- Pharmaceuticals – Immedica operates in the pharmaceutical sector, specializing in rare and specialty diseases.
- Investment Management – KKR and Impilo represent firms significant in private equity and investment management.
Financials
- 41 billion – The size of CVC's global credit management business.
Participants
Name | Role | Type | Description |
---|---|---|---|
Immedica Pharma | Target Company | Company | A Swedish pharmaceutical company focusing on drugs for rare and specialty diseases. |
KKR | Bidding Company | Company | A global investment firm involved in the acquisition of Immedica Pharma. |
Impilo | Bidding Company | Company | A Nordic healthcare investment firm partaking in the acquisition of Immedica Pharma. |
CVC Credit | Debt Provider | Company | The credit management arm of CVC Capital Partners providing debt facilities for the acquisition. |
CVC Capital Partners | Credit Management | Company | An international private equity and investment advisory firm. |
Moris Nachmias | Managing Director | Person | A Managing Director at CVC Credit commenting on the acquisition. |